To further assess the efficacy and safety of recombinant human endostatin (rh-endostatin), a Phase III, multicenter, prospective, randomized, controlled clinical trial was conducted. Patients to be treated with neoadjuvant docetaxel and epirubicin (DE) or DE plus rh-endostatin (DEE) were eligible for this trial. The primary endpoint was clinical/pathological response. Secondary endpoints included adverse events and quality of life (QOL). Finally, 803 patients were enrolled and randomly assigned to receive DE (n 5 402) or DEE (n 5 401) regimen. After three cycles of neoadjuvant therapy, "complete response" achieved in 14.2% of patients in DEE group versus 6.7% in DE group, "partial response" achieved in 76.8% versus 71.1%, while "stable disease" in 6.0% versus 18.9%, "progressive disease" in 3.0% versus 3.2% of patients. The rate of objective response in DEE and DE group was 91.0% and 77.9%, respectively (p < 0.001). In spite of a relatively higher pathological complete response achieved following the combination therapy, no significant difference was found between two arms. Adverse events were mostly of Grades 1-2. No significant difference in adverse event and QOL was found between the two arms. In conclusion, the combination of chemotherapy and rh-endostatin achieved better outcomes than chemotherapy alone, and thus can be considered as a promising therapeutic strategy for breast cancer.
Neoadjuvant systemic chemotherapy administered prior to surgery has currently been paid much attention because of its outstanding superiorities in degrading the pathological stage of inoperable breast cancer. 1 The reduced size of tumor, together with the regression of lymph node metastases, presents unique advantages in making patients with larger tumors available for breast conserving surgery (BCS). 2 von Minckwitz 3 reported that approximately 10-30% of patients who were initially candidates for mastectomy were finally treated with BCS after neoadjuvant therapy. Meanwhile, several clinical trials have been registered, such as EORTC 10902 and Fem-024, to explore effective neoadjuvant drugs. 4, 5 In particular, neoadjuvant chemotherapy has been demonstrated to enhance prognostic pathological complete response (pCR), as well as long-term disease-free survival (DFS) and overall survival (OS). 2 Antiangiogenesis represents a promising approach to the treatment of malignant disease given that tumor growth predominantly depends on its angiogenesis status. 6 rhEndostatin, an antiangiogenic drug developed in China, has been proved to markedly inhibit endothelial cell proliferation, migration, invasion and tube formation. 7 As reported, rhendostatin was first approved for non-small-cell lung cancer (NSCLC) treatment. The benefit afforded by the addition of rh-endostatin to chemotherapy in NSCLC has been confirmed in many clinical studies, thereby suggesting the further benefits derived by rh-endostatin for other solid tumors, including breast cancer. 8, 9 The first prospective, randomized, Phase II study (ClinicalTrials.gov Identifier: NCT00604435) was registered by our team on January 2008, to gauge the impact of rh-endostatin on breast cancer therapy. The data based on 68 participants showed that the combination of rhendostatin with chemotherapy produced a higher tumor response rate without increasing toxicity, as compared to chemotherapy alone. 10 Part of the results was presented in the 47th Annual Meeting of ASCO (American Society of Clinical Oncology).
Based on the compelling data from Phase II trial, a Phase III trial was designed and undertaken to further assess the efficacy and safety profiles of rh-endostatin, with the statistically estimated enrollment number set at 800 (CBCRT01, ClinicalTrials.gov Identifier: NCT01479036).
Methods

Study design and participants
This is a multicenter, prospective, randomized, controlled, Phase III clinical trial. The First and Second Affiliated Hospital of Xi'an Jiaotong University, The Tumor Hospital of Shaanxi Province, The Second Affiliated Hospital of Fourth Military Medical University were involved. Patients with core-biopsy confirmed breast cancer and to be treated with neoadjuvant systemic therapy are eligible for entry into our study. The inclusion criteria were (1) histologically confirmed invasive breast cancer (core needle biopsy for breast cancer diagnosis and fine needle aspiration for lymph node metastasis diagnosis), (2) clinical stages IIA-IIIC, (3) age 18-70 years, (4) ECOG performance status 0-2, (5) no evidence of distant metastasis, (6) no previous therapy, (7) normal hematologic function, (8) left ventricular ejection fraction >50%, (9) no abnormality of renal or liver function and (10) written informed consent. Exclusion criteria included (1) with allergic constitution or possible allergic reflection to drugs to be used in our study, (2) any concurrent uncontrolled medical or psychiatric disorder, (3) history of severe heart diseases, including congestive heart failure, unstable angina, uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood pressure, or heart valve disease, (4) history of bleeding diathesis and (5) being pregnant or nursing.
The study protocol has been approved by an independent ethics committee of Fourth Military Medical University. The study was undertaken in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. All patients were asked to provide written informed consent before enrollment.
Randomization and masking
The enrolled patients were randomly assigned (1:1) via a computer generating schedule in SAS, to receive either neoadjuvant docetaxel plus epirubicin (DE) or neoadjuvant DE plus rh-endostatin (DEE). Patients remained masked to the assigned treatment until the final cycle of adjuvant therapy. Premature unmasking of study drug assignment was only allowed in case of emergency.
Sample size estimation
The sample size was estimated for each treatment according to the indicators of complete response (CR) and partial response (PR). Based on the previous study, the percentages of CP and PR were about 6% and 50%, respectively, in the group of DE. 10 We estimated that the two percentages could go up to 12% and 60%, respectively, in the group of DEE. So the estimated sample size for each group was 332 participants for CR and 227 participants for PR given A of 0.05 and power of 90%. Therefore, 332 for each treatment group was used as sample size in our study. Considering 20% of loss in follow-up, final sample size estimated for each treatment group was set at 398 and the total sample size for both treatment groups was 796 participants. All patients received mammography, ultrasound, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and positron emission tomography (PET) scanning pre-and postneoadjuvant therapy, and then underwent surgical resection. After surgery, three to six cycles of adjuvant What's new? Because solid tumors rely on new blood vessels to grow larger and to metastasize, a number of antiangiogenic drugs are now used in the clinic or are in development. In this Phase III clinical study in breast-cancer patients, the authors tested a new drug candidate called "recombinant human endostatin" (rh-endostatin), in combination with neoadjuvant chemotherapy. They found that the combination yielded significantly better outcomes than the chemotherapy alone. These results support rhendostatin as part of a promising therapeutic strategy for breast cancer.
Treatment procedures
chemotherapy were given to all participants based on the terms of clinical staging, histological grade, clinical and pathological response, apoptosis index and biological markers such as hormonal receptor status, Ki-67 index and human epidermal growth factor receptor 2 (HER2) expression. HER2-positive patients received trastuzumab after surgery, beginning with a loading dose of 4 mg/kg body weight and followed by weekly doses of 2 mg/kg for 51 weeks. Radiotherapy was given to those who were candidate at study entry and those receiving breast conservation. Patients diagnosed with positive estrogen receptor and/or progesterone receptor received endocrine therapy.
Study endpoints
The primary endpoint was clinical and pathological response. Tumor volume was measured by DCE-MRI and the clinical response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 11 and classified as CR (disappearance of all target lesions), PR (at least a 30% decrease in the sum of the longest diameter of target lesions), stable disease (SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD] ) and PD (at least a 20% increase in the sum of the longest diameter of target lesions or the appearance of one or more new lesions). Tumor classified as CR or PR was defined as objective response (OR), and that classified as SD or PD was defined as no response (NR). Pathological response of breast tumor was defined as follows: (a) CR (pCR), no residual viable invasive tumor, i.e., only in situ disease or tumor stroma remained and (b) nonresponse, any viable tumor.
The secondary endpoint was (1) the number of participants presenting adverse events, (2) the number of adverse events reported during neoadjuvant therapy and (3) quality of life (QOL) scores. The adverse events were graded based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. 12 QOL was evaluated using the European Organization for Research and Treatment of Cancer Quality of Life of Questionnaire (EORTC QLQC30) questionnaire at study entry, and prior to surgery. 13 In addition, the parameters of tumor metabolism and blood supply, as demonstrated by PET and DCE-MRI, were collected and analyzed.
DCE-MRI
DCE-MRI was given to all patients pre-and postneoadjuvant therapy. Patients were kept in the prone position and examined with a 3.0 T scanner (Magnetom Trio, Siemens, Germany) and a dedicated phased array breast-surface coil. Routine magnetic imaging for morphology of the breast was first acquired using T2-tirm in transverse and sagittal planes (repetition time-5 6,490 msec, echo time 5 60 msec, flip angle 5 1208, slice thickness 5 4 mm, interslice gap 5 0.4 mm and acquisition matrix 5 320 3 320). A nonenhanced, fat-suppressed, threedimensional fast low-angle shot T1 sequence was acquired in the transverse plane (repetition time 5 7 msec, echo time 5 3 msec, slice thickness 5 1 mm, interslice gap 5 0.2 mm, acquisition matrix 5 450 3 300 and flip angle 5 150). Then the dynamic study was performed in the transverse plane using a threedimensional fast low-angle shot five times 20 sec after the bolus injection of gadolinium diethylene-triamine pentaacetic acid (Magnevist, Schering, Berlin, Germany). Gd-DTPA was infused in the antecubital vein at a dosage of 0.1 mmol/kg body weight by a power injector at a speed of 2 mL/sec and followed by a 20 mL saline flush at the same speed.
Image analysis
The MR images were analyzed by two radiologists who were blind to treatment schedule. Image subtraction was performed from all series of contrast-enhanced images to improve visualization of contrast uptake areas and to evaluate their morphologies. The time-signal intensity curve was attained through the Mean Curve Program provided by Siemens. The subtraction of the basal acquisition from early contrast-enhanced slices was loaded into Image J, version 1.40 (National Institutes of Health, Bethesda, MD), for tumor volume evaluation. The signal enhancement ratio (SER) was used to compare early and late enhancement in the lesions to reflect the rate of contrast washout in the tumor. SER was calculated by SER 5 (S1 -S0)/(S2 -S1), where S0 was the baseline signal intensity, S1 and S2 was the signal measured at 90 and 270 sec, respectively, after contrast delivery. A pharmacokinetic, two-compartment, bidirectional exchange model was used for pharmacokinetic analysis of the images to evaluate the vasculature permeability and tumor perfusion. A fixed-T1, fuzzy c-means method, which combines a fixed-T1, fuzzy c-means technique with a reference region model and removes the need for measuring the arterial input function or baseline T1 or T1(0), was used to obtain two pharmacokinetic parameters. They were K trans (forward transfer constant from the vascular space to the tumors), which primarily reflects the wash-in of contrast agents, and v e (extravascular extracellular volume fraction), which primarily represents the overall leakage space of the tumor. The data were processed with Matlab (The MathWorks, Natick, MA).
PET/CT scan
PET/CT scan was performed, at study entry and prior to surgery, with a hybrid PET/CT scanner (Biograph 40; Siemens Medical Solutions, Malvern, PA). All patients were kept fasting for at least 6 hr to ensure glucose blood levels below 10 mmol/L before an intravenous injection of 18 F-FDG (7.40 MBq/kg). CT scanning from the proximal thighs to head was initiated 1 hr after FDG injection with a 64-slice helical CT acquisition (140 kV, 90 mA, a slice thickness of 3 mm, a 50 cm displayed field of view, and a rotational speed of 0.75 sec per rotation). Immediately after CT scanning, PET emission scan that covered the identical field was acquired. PET images were reconstructed with CT-derived attenuation correction using ordered-subset expectation maximization software.
Image analysis
The PET/CT data were interpreted on Xeleris workstation by two double-blind nuclear physicians. All the lesion volumes were defined by manually defining the volume of interest (VOI), referred to as the FDG-VOI on the 18 FDG PET/CT, and the hottest spot in the tumor foci was noted as the peak values of standardized uptake value (SUV). After neoadjuvant therapy, the VOI was copied onto the images of the second PET/CT scans. Therapy-induced metabolic alteration in tumors was defined as the reduction rate of SUV and measured by percentage changes in SUV before and after neoadjuvant therapy.
Statistical analysis
All participants were reminded for reexamination by specified research nurses. Benefit from the strategies including consultation in priority and remission of reexamination fee, there is only six patients out of the study, the rate of compliance was up to 99.26%. Considering the little influence of people loss to follow-up on the results, a per-protocol analysis was adopted in data analysis. Two investigators independently extracted the data using a predesigned data extraction form. Discrepancies were resolved by discussion. Normal distribution data were represented by mean 6 standard deviation. Student's t-test was used to compare the mean after checking the homogeneity of variance. Enumeration data was compared using v 2 test, and unadjusted odds ratio and adjusted odd ratio were estimated by logistic regression for each indictor. Adjusting factors included center, age, menopausal status, histology, PR status, ER status, HER2 status, ECOG performance status, histology, axillary lymph node status and clinical stage. p < 0.05 was considered statistically significant. SPSS 16.0 for windows was used for statistical analysis.
Results
Baseline characteristics
Between October 2011 and February 2015, 821 patients were assessed for eligibility. Of them, 12 failed to meet the inclusion criteria. The remained 809 patients were randomly enrolled into our study, with 404 allocated to control group receiving DE regimen, and 405 to experiment group receiving DEE. During therapeutic process, 2 and 4 patients in two groups, respectively, failed to complete the scheduled therapy, leaving 803 participants assessable for final evaluation with 402 in DE and 401 in DEE group (Fig. 1) . The baseline characteristics including age, comorbid diseases, menopausal status, histology, molecular subtype, ECOG performance status, axillary lymph node status and clinical stage are listed in Table 1 . All these factors were well balanced between two arms. In spite of a relative higher pCR rate achieved following rhendostatin combination therapy, no significant difference was found between two arms (Table 2) .
Tumor blood supply assessed by DCE-MRI
A total of 1,440 DCE-MRI scans from 720 patients were obtained for analysis. There were 35 and 48 cases, respectively, in DE and DEE groups, failed to receive DCE-MRI for suspected allergy to gadolinium. It was revealed that except for obvious reduction of tumor volume, the combination of rh-endostatin and chemotherapy produced evident inhibition on tumor angiogenesis (Figs. 2a-2d ). Quantitative analysis showed no difference in tumor SER, v e or K trans between the two arms prior to treatment. After treatment, SER decreased from 233.05 6 96.11% to 120.80 6 54.15%, v e decreased from 0.78 6 0.24 to 0.50 6 0. 16 
Tumor metabolism evaluated by PET
The biological changes pre-and postneoadjuvant therapy were studied by PET (Figs. 2e and 2f) . A total of 1,528 PET/ CT scans from 764 patients (391 in DE and 373 in DEE arms) were eligible for analysis. All the tumors were well visualized on PET/CT images as abnormal FDG accumulation in breast tissues. In the baseline PET/CT scan, the SUV peak of breast tumors ranged from 2.1 to 20.3 (mean 5 7.62 6 3.81) and no difference was found between the two arms. After three cycles of neoadjuvant therapy, the SUV peak of targeted lesions fell from 7.58 6 3.62 to 2.97 6 2.06 in DE group, with the mean reduction rate of 61% (range, 14-88%). In contrast, SUV fell from 7.66 6 4.01 to 1.98 6 1.75, a decrease of 74% (range, 10-93%), in DEE group, with significant difference from DE (74% vs. 61%, p < 0.001).
Adverse events
The incidence of adverse events is shown in Table 3 . The total incidence of adverse events was 83.5% and 86.2%, respectively, in DEE and DE arm. Most of the adverse events were graded 1-2, such as neutropenia, leukopenia, alopecia, asthenia, fatigue, nausea/vomiting and dyspepsia. Grade 3-4 adverse events mainly included neutropenia, leucopenia, nausea and vomiting. No significant difference was found between the two arms, either in the incidence of overall adverse events or in the incidence of Grade 3-4 adverse events.
Sensitive analysis
All the factors probably influencing the clinical response were stratified and analyzed. The factors included age, menopausal status, histology, molecular subtype, ECOG performance status, axillary lymph node status and clinical stage (Table 4) . Results showed that except for patients with lobular or other histologic types, or with triple-negative breast cancer, DEE regimen produced more OR than DE regimen in other subpopulations of breast cancer.
Quality of life
QOL and life expectancy of breast cancer patients may be hampered by complications or adverse events. A total of 758 patients finished the questionnaire investigation with 383 in DE and 375 in DEE group. QQL score of DE group were 54.61 6 11.34 and 55.32 6 15.79, respectively, before and after treatment, while that of DEE group were 58.15 6 13.29 and 53.91 6 14.07. There was no significant difference between the two groups either before or after treatment (p > 0.05), indicating the little impact of rh-endostatin upon QOL.
Discussion
Systemic treatment of breast cancer is more sophisticated and specific, characterized by multiple cancer targets. One promising strategy is to target the proangiogenic VEGF, either by ligand sequestration (preventing VEGF receptor binding) or by inhibiting downstream receptor signaling. Rh-endostatin is such a new recombinant humanized endostatin expressed and purified in Escherichia coli. Although DE have been accepted as a "standard" regimen in adjuvant and neoadjuvant settings, especially for women with rapidly progressive disease, the combination of DE and rh-endostatin has never been explored until our previous Phase II study. 14 To the best of our knowledge, this was the first registered Phase III clinical trial to evaluate the role of rh- endostatin in breast cancer therapy. The primary endpoint was clinical/pathological response. The secondary endpoints included adverse events and QOL. It was confirmed that the addition of rh-endostatin to DE chemotherapy resulted in a significant improvement of overall OR. Stratification analysis showed that most of patients might benefit from the combination therapy, except those with nonductal or triple-negative breast cancer. No significant difference was observed in the incidence of adverse events and QOL score.
In contrast to western countries, breast cancer affects relatively younger women in China, over half of them are premenopausal, indicating the significance to develop novel therapeutic strategies applicable to young patients. 15 The stratification analysis of our Phase II trial showed that rhendostatin was more effective for premenopausal patients. 10 Findings in the present study supported this conclusion. In addition, the enhanced efficacy was also observed in periand postmenopausal patients.
Locally advanced breast cancer (LABC) is an aggressive form of breast cancer and characterized by a relatively poor prognosis. In accordance with the impact of rh-endostatin on other advanced cancer, such as advanced NSCLC, advanced colorectal cancer, advanced gastrointestinal cancer and advanced esophageal cancer, [16] [17] [18] [19] here we found that rhendostatin produced a higher OR in Stage III breast cancer, supporting it to be used as first-line therapy for LABC. As reported, some features of breast cancer, such as blood perfusion and metabolism, may influence its response to chemotherapy. 20 A low ratio of glucose metabolism to glucose delivery after therapy predicted a favorable outcome. 21 LABC has abundant blood flow and vigorous metabolism, which might guarantee the positive response to antiangiogenic treatment. 22 The increase of antiangiogenic therapeutic approaches in the clinic brings with it an urgent need for new imaging techniques capable of providing earlier indications of treatment efficacy. Functional imaging, such as contrast-enhanced ultrasonographic imaging, contrast-enhanced CT, DCE-MRI and PET, is being increasingly utilized for the evaluation of antiangiogenic and anticancer compounds therapy in early clinical trials. Unlike the conventional imaging techniques, such as mammography, ultrasound and CT, which measure the reduction of morphological size, the functional imaging might depict biological response after neoadjuvant therapy. DCE-MRI can be used to evaluate microvessel perfusion and permeability of tumor vasculature, which could predict clinical and pathologic response to neoadjuvant chemotherapy in breast cancer. 23 Unlike microvessel density (MVD) measurement on focal regions, DCE-MRI provides information on whole tumor volumes, which is more informative because tumor vasculature is heterogeneously distributed throughout the tumor. 24 DCE-MRI in our study showed satisfactory antiangiogenesis and antitumor effects after the combination therapy. Quantitative analysis verified that DEE regimen resulted in more reductions of SER and K trans than DE regimen. As we know, SER and K trans represent contrast washout and wash-in, respectively, in tumor entity. This finding supported the antiangiogenesis effect of rh-endostatin upon breast cancer. PET is used to measure tumor metabolism and provide a valuable insight into the biological response of tumors undergoing neoadjuvant chemotherapy. 24 Ogino et al. 25 have demonstrated that FDG-PET/CT can differentiate responders from nonresponders in LABC. In the present study, PET/CT indicated a higher SUV decrease of targeted lesions after combination treatment, as compared to chemotherapy alone. The combination of rh-endostatin with DE was associated with several incidences of adverse events, mostly of Grades 1 and 2. The most frequently reported Grade 3 and 4 adverse events included neutropenia, leukopenia, nausea and vomiting. No significant difference was found between two groups, either in the incidence of overall adverse events or in the incidence of Grade 3/4 adverse events. Thus far, no treatment-relative death due to adverse events was reported, suggesting the safety of rh-endostatin.
Several limitations should be considered when interpreting our results. First, no other relative studies could be referred at the neoadjuvant setting in breast cancer study. Second, the subsequent follow-up has not yet been proceeded to investigate the survival of participants, which would be helpful to better understanding the value of the combination of rhendostatin and chemotherapy. Third, the outcome of the present study was limited, much more critical endpoint should be considered.
In summary, our study indicated that the combination of rh-endostatin with DE is safe and effective for breast cancer therapy in neoadjuvant setting. Our findings supported the further investigation and application of rh-endostatin in breast cancer. 
